These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2516085)

  • 21. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
    BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa.
    Nicas TI; Iglewski BH
    Antibiot Chemother (1971); 1985; 36():40-8. PubMed ID: 2988426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa.
    Beaulac C; Sachetelli S; Lagacé J
    J Drug Target; 1999; 7(1):33-41. PubMed ID: 10614813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant Pseudomonas exoenzyme S and exoenzyme S from Pseudomonas aeruginosa DG1 share the ability to stimulate T lymphocyte proliferation.
    Bruno TF; Woods DE; Storey DG; Mody CH
    Can J Microbiol; 1999 Jul; 45(7):607-11. PubMed ID: 10497789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
    Wang Q; Li H; Zhou J; Zhong M; Zhu D; Feng N; Liu F; Bai C; Song Y
    Respir Physiol Neurobiol; 2014 Mar; 193():21-8. PubMed ID: 24418353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alteration of pulmonary structure by Pseudomonas aeruginosa exoenzyme S.
    Woods DE; Hwang WS; Shahrabadi MS; Que JU
    J Med Microbiol; 1988 Jun; 26(2):133-41. PubMed ID: 3133480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium.
    Collie D; Glendinning L; Govan J; Wright S; Thornton E; Tennant P; Doherty C; McLachlan G
    PLoS One; 2015; 10(11):e0142097. PubMed ID: 26544950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model.
    Gilleland HE; Gilleland LB; Fowler MR
    J Med Microbiol; 1993 Feb; 38(2):79-86. PubMed ID: 8429543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-administration of aqueous ginseng extract with tobramycin stimulates the pro-inflammatory response and promotes the killing of Pseudomonas aeruginosa in the lungs of infected rats.
    Alipour M; Omri A; Lui EM; Suntres ZE
    Can J Physiol Pharmacol; 2013 Nov; 91(11):935-40. PubMed ID: 24117261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
    Lu Q; Yu J; Bao L; Ran T; Zhong H
    Chemotherapy; 2013; 59(1):51-6. PubMed ID: 23816803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antibiotic therapy of cystic fibrosis in children].
    Kapranov NI; Shabalova LA; Kashirskaia NIu; SimonovaO OI; Voronkova AIu; Osipova IA; Semykin SIu; Polikarpova SV; Postnikov SS
    Antibiot Khimioter; 2001; 46(2):26-32. PubMed ID: 11544748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of antibiotic resistance and virulence factors in pigmented and non-pigmented Pseudomonas aeruginosa.
    Finlayson EA; Brown PD
    West Indian Med J; 2011 Jan; 60(1):24-32. PubMed ID: 21809707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
    Fernández-Barat L; Ciofu O; Kragh KN; Pressler T; Johansen U; Motos A; Torres A; Hoiby N
    J Cyst Fibros; 2017 Mar; 16(2):222-229. PubMed ID: 27651273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo regulation of virulence in Pseudomonas aeruginosa associated with genetic rearrangement.
    Woods DE; Sokol PA; Bryan LE; Storey DG; Mattingly SJ; Vogel HJ; Ceri H
    J Infect Dis; 1991 Jan; 163(1):143-9. PubMed ID: 1824596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis].
    Coban AY; Ciftci A; Onuk EE; Erturan Z; Tanriverdi Cayci Y; Durupinar B
    Mikrobiyol Bul; 2009 Oct; 43(4):563-73. PubMed ID: 20084909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury.
    Kudoh I; Wiener-Kronish JP; Hashimoto S; Pittet JF; Frank D
    Am J Physiol; 1994 Nov; 267(5 Pt 1):L551-6. PubMed ID: 7977765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
    Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudomonas aeruginosa exoenzyme S.
    Coburn J
    Curr Top Microbiol Immunol; 1992; 175():133-43. PubMed ID: 1321018
    [No Abstract]   [Full Text] [Related]  

  • 40. Clearance of Pseudomonas aeruginosa in different rat lung models.
    Döring G; Dauner HM
    Am Rev Respir Dis; 1988 Nov; 138(5):1249-53. PubMed ID: 3144214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.